These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 12842774)

  • 1. Skin as a route of exposure and sensitization in chronic beryllium disease.
    Tinkle SS; Antonini JM; Rich BA; Roberts JR; Salmen R; DePree K; Adkins EJ
    Environ Health Perspect; 2003 Jul; 111(9):1202-8. PubMed ID: 12842774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic granulomatous pneumonia and lymphocytic responses induced by inhaled beryllium metal in A/J and C3H/HeJ mice.
    Nikula KJ; Swafford DS; Hoover MD; Tohulka MD; Finch GL
    Toxicol Pathol; 1997; 25(1):2-12. PubMed ID: 9061844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant.
    Henneberger PK; Cumro D; Deubner DD; Kent MS; McCawley M; Kreiss K
    Int Arch Occup Environ Health; 2001 Apr; 74(3):167-76. PubMed ID: 11355290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of the blood beryllium lymphocyte proliferation test.
    Newman LS
    Environ Health Perspect; 1996 Oct; 104 Suppl 5(Suppl 5):953-6. PubMed ID: 8933041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cluster of Beryllium Sensitization Traced to the Presence of Beryllium in Concrete Dust.
    Frye BC; Quartucci C; Rakete S; Grubanovic A; Höhne K; Mangold F; Gieré R; Müller-Quernheim J; Zissel G
    Chest; 2021 Mar; 159(3):1084-1093. PubMed ID: 32926872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of lymphocyte proliferation tests in assessing occupational sensitization and disease.
    Hines SE; Pacheco K; Maier LA
    Curr Opin Allergy Clin Immunol; 2012 Apr; 12(2):102-10. PubMed ID: 22306552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TLR9 and IL-1R1 Promote Mobilization of Pulmonary Dendritic Cells during Beryllium Sensitization.
    Wade MF; Collins MK; Richards D; Mack DG; Martin AK; Dinarello CA; Fontenot AP; McKee AS
    J Immunol; 2018 Oct; 201(8):2232-2243. PubMed ID: 30185516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy of a program to prevent beryllium disease.
    Thomas CA; Deubner DC; Stanton ML; Kreiss K; Schuler CR
    Am J Ind Med; 2013 Jul; 56(7):733-41. PubMed ID: 23450749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenetic factors in beryllium sensitization and chronic beryllium disease.
    Weston A; Snyder J; McCanlies EC; Schuler CR; Andrew ME; Kreiss K; Demchuk E
    Mutat Res; 2005 Dec; 592(1-2):68-78. PubMed ID: 16054169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the berylliosis-associated HLA-DPGlu69 supratypic variant in determining the response to beryllium in a blood T-cells beryllium-stimulated proliferation test.
    Amicosante M; Deubner D; Saltini C
    Sarcoidosis Vasc Diffuse Lung Dis; 2005 Oct; 22(3):175-9. PubMed ID: 16315779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of proliferation tests to evaluate the effects of complexing agents on beryllium toxicity.
    Stephan CH; Sauvé S; Fournier M; Brousseau P
    J Appl Toxicol; 2009 Jan; 29(1):27-35. PubMed ID: 18785683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarcoidosis and chronic beryllium disease: similarities and differences.
    Mayer AS; Hamzeh N; Maier LA
    Semin Respir Crit Care Med; 2014 Jun; 35(3):316-29. PubMed ID: 25007084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Process-related risk of beryllium sensitization and disease in a copper-beryllium alloy facility.
    Schuler CR; Kent MS; Deubner DC; Berakis MT; McCawley M; Henneberger PK; Rossman MD; Kreiss K
    Am J Ind Med; 2005 Mar; 47(3):195-205. PubMed ID: 15712254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-alpha polymorphisms in chronic beryllium disease and beryllium sensitization.
    McCanlies EC; Schuler CR; Kreiss K; Frye BL; Ensey JS; Weston A
    J Occup Environ Med; 2007 Apr; 49(4):446-52. PubMed ID: 17426528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in dissolution behavior in a phagolysosomal simulant fluid for single-constituent and multi-constituent materials associated with beryllium sensitization and chronic beryllium disease.
    Stefaniak AB; Day GA; Hoover MD; Breysse PN; Scripsick RC
    Toxicol In Vitro; 2006 Feb; 20(1):82-95. PubMed ID: 16061346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitization and chronic beryllium disease at a primary manufacturing facility, part 3: exposure-response among short-term workers.
    Schuler CR; Virji MA; Deubner DC; Stanton ML; Stefaniak AB; Day GA; Park JY; Kent MS; Sparks R; Kreiss K
    Scand J Work Environ Health; 2012 May; 38(3):270-81. PubMed ID: 21877099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model for optimization of biomarker testing frequency to minimize disease and cost: example of beryllium sensitization testing.
    Judd NL; Griffith WC; Takaro T; Faustman EM
    Risk Anal; 2003 Dec; 23(6):1211-20. PubMed ID: 14641896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunology of chronic beryllium disease.
    Samuel G; Maier LA
    Curr Opin Allergy Clin Immunol; 2008 Apr; 8(2):126-34. PubMed ID: 18317020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review: Progression of beryllium sensitization to chronic beryllium disease.
    Seidler A; Euler U; Müller-Quernheim J; Gaede KI; Latza U; Groneberg D; Letzel S
    Occup Med (Lond); 2012 Oct; 62(7):506-13. PubMed ID: 22705916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of beryllium oxide particles: an in vitro study in the murine J774A.1 macrophage cell line model.
    Day GA; Hoover MD; Stefaniak AB; Dickerson RM; Peterson EJ; Esmen NA; Scripsick RC
    Exp Lung Res; 2005 Apr; 31(3):341-60. PubMed ID: 15962713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.